NewAmsterdam Pharma (NAMS) Prepaid Assets (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Prepaid Assets of $20.6 million for Q1 2026, down 45.98% sequentially from $38.1 million in Q4 2025, and up 133.41% YoY from $8.8 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Prepaid Assets (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Prepaid Assets for 6 years, with the latest figure at $20.6 million in Q1 2026.
- Quarterly Prepaid Assets rose 133.41% year-over-year to $20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (up 133.41% YoY) and the FY2025 annual result came in at $38.1 million, up 57.13% from the prior year.
- Prepaid Assets eased to $20.6 million in Q1 2026 per NAMS's latest filing, from $38.1 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $38.1 million in Q4 2025 and troughed at $6.3 million in Q2 2023.
- A 5-year average of $17.3 million and a median of $14.9 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets surged 358.48% in 2022, then declined 18.97% in 2023.
- Over 5 years, Prepaid Assets stood at $7.8 million in 2022, then retreated by 18.97% to $6.3 million in 2023, then jumped by 282.78% to $24.3 million in 2024, then surged by 57.13% to $38.1 million in 2025, then slumped by 45.98% to $20.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $20.6 million, $38.1 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.00 Mn |
| Mar 31, 2026 | 20.60 Mn |
| Dec 31, 2025 | 38.14 Mn |
| Sep 30, 2025 | 28.07 Mn |
| Jun 30, 2025 | 30.69 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Dec 31, 2024 | 24.27 Mn |
| Sep 30, 2024 | 15.15 Mn |
| Jun 30, 2024 | 14.64 Mn |
| Mar 31, 2024 | 6.68 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Jun 30, 2023 | 6.28 Mn |
| Dec 31, 2022 | 7.83 Mn |
| Dec 31, 2021 | 1.71 Mn |